- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01214005
Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls (WREN)
April 26, 2012 updated by: Jennifer Tidey, Brown University
This project tests two hypotheses concerning the low smoking cessation rates in smokers with schizophrenia.
The first hypothesis is that smokers with schizophrenia experience stronger and more sustained effects of smoking abstinence on negative mood and smoking urge than control smokers without psychiatric illness.
The second hypothesis is that smokers with schizophrenia experience stronger reinforcing effects of a smoking lapse (i.e., more rewarding effects of smoking after a period of abstinence) than control smokers without psychiatric illness.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this study, smokers with schizophrenia and smokers without psychiatric illness participate in a nicotine preference task before and after a 3-day period of continuous smoking abstinence.
The investigators will experimentally control abstinence by providing participants with high-value cash incentives contingent upon smoking abstinence verified with breath carbon monoxide levels.
The investigators will measure nicotine withdrawal and smoking urge during the abstinence period.
In the nicotine preference task, participants will make choices between nicotine-containing and denicotinized cigarette puffs to provide a measure of nicotine reinforcement, and the investigators will also measure the effects of smoking on mood.
After the second nicotine preference task, participants will receive a small-value reinforcer if they continue to abstain for another day, and the investigators will measure time to the second lapse.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02912
- Brown University, 121 South Main Street
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- cigarette smokers, 20-50 cigarettes per day
- schizophrenia or no psychiatric illness
- age 18 or older
- male or female
Exclusion Criteria:
- unstable symptoms or medication
- not interested in quitting smoking within 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: schizophrenia
Smokers with schizophrenia or schizoaffective disorder
|
3 days of biologically-confirmed smoking abstinence
|
|
Other: non-psychiatric
smokers without psychiatric illness
|
3 days of biologically-confirmed smoking abstinence
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Withdrawal symptoms
Time Frame: 3 days
|
negative mood related to nicotine withdrawal
|
3 days
|
|
urge to smoke
Time Frame: 3 days
|
craving for smoking
|
3 days
|
|
nicotine preference
Time Frame: before and after 3 days of abstinence
|
choice for nicotine puffs versus denicotinized cigarette puffs
|
before and after 3 days of abstinence
|
|
positive and negative mood
Time Frame: before and after 3 days of abstinence
|
positive and negative mood scale
|
before and after 3 days of abstinence
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
time to lapse
Time Frame: 192 hours
|
time between smoking behavior in the laboratory and first cigarette outside of the laboratory
|
192 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jennifer Tidey, Ph.D., Brown University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
October 1, 2010
First Submitted That Met QC Criteria
October 1, 2010
First Posted (Estimate)
October 4, 2010
Study Record Updates
Last Update Posted (Estimate)
April 27, 2012
Last Update Submitted That Met QC Criteria
April 26, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R21DA026829 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Ole Köhler-ForsbergAarhus University HospitalRecruiting
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
-
Bradley LegaRecruiting
-
Central Institute of Mental Health, MannheimRecruitingSchizophrenia | Treatment Resistant SchizophreniaGermany
Clinical Trials on smoking abstinence
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA)Completed
-
RAI Services CompanyCompleted
-
Duke UniversityNational Institutes of Health (NIH)Completed
-
Duke UniversityNational Institutes of Health (NIH)Completed
-
Philip Morris Products S.A.CompletedSmoking | Inflammation | Oxidative Stress | Smoking AbstinenceGermany, Japan, Czechia, Bulgaria, Poland, Greece
-
Babes-Bolyai UniversityCompleted
-
University of California, IrvineNational Institute on Drug Abuse (NIDA)CompletedSmoking | ADHD | Withdrawal NicotineUnited States
-
University of OklahomaNational Institute on Drug Abuse (NIDA); Oklahoma State UniversityCompletedNicotine Dependence | Cigarette Smoking | Nicotine WithdrawalUnited States
-
Duke UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Food and Drug Administration (FDA)TerminatedCigarette Smoking | Nicotine WithdrawalUnited States
-
University of California, San FranciscoCompletedCigarette SmokingUnited States